Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8428009 | 0.87 | LTA4H (0.55) | LTA4HKDM4ETSHRKDRALDH1A1 | |
| SCHEMBL14393407 | 0.85 | LTA4H (0.53) | LTA4HKDM4ETSHRKDRALDH1A1 | |
| SCHEMBL8245742 | 0.84 | LTA4H (0.52) | LTA4HKDM4ETSHRKDRALDH1A1 | |
| SCHEMBL13803105 | 0.83 | SYK (0.55) | LTA4HKDM4ETSHRHTTPOLB | |
| SCHEMBL13855801 | 0.81 | POLB (0.59) | KDM4ETSHRKDRALDH1A1POLB | |
| SCHEMBL2718979 | 0.81 | KDM4E (0.57) | LTA4HKDM4ETSHRKDRALDH1A1 | |
| SCHEMBL2671540 | 0.81 | ALDH1A1 (0.62) | LTA4HKDM4ETSHRKDRALDH1A1 | |
| SCHEMBL13849557 | 0.81 | KDM4E (0.64) | LTA4HKDM4ETSHRALDH1A1HTT | |
| SCHEMBL18707215 | 0.80 | KDR (0.55) | KDM4ETSHRKDRALDH1A1MAPT | |
| SCHEMBL20575879 | 0.79 | KDR (0.54) | KDM4ETSHRKDRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | LTA4H 1770/4885KDM4E 1793/4885TSHR 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.